Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Below averageWe are a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases. We target therapeutic areas in which current treatments leave room for improvements in efficacy, safety, and/or dosing convenience. We believe there is significant potential in these areas, for better medicines that address unmet needs, improve outcomes, and expand treatment options for patients.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Q1 2026 · $141.0KThe company’s own SEC segment disclosure.
- Collaboration$135.0K96%
- License$6.0K4%
Viridian Therapeutics, Inc. (VRDN) reported revenue of $284K in Q2 2026 (quarter ended June 30, 2026), up 279% from the same quarter a year earlier. That came with net loss of $127M. For the full year FY2025, revenue was $71M (+23360% year on year) and net income −$343M. Its largest product in 2026-Q1 was Collaboration at $135K, 96% of the disclosed total, just ahead of License at 4.3%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.